Stephanie Piper focuses her practice on patent law and has experience guiding clients through every stage of a litigation from performing pre-suit evaluations, initiating suits, and pursuing fact and expert discovery to trial on the merits and appeals. She also advises clients on freedom to operate analyses and related diligence matters. She has significant experience representing pharmaceutical companies in complex Hatch-Waxman litigation. Ms. Piper attended Columbia Law School where she was a Harlan Fiske Stone Scholar and the Notes Editor of the Columbia Science and Technology Law Review. She graduated magna cum laude from New York University with undergraduate degrees in History and Political Science.
- Pfizer, patent infringement ANDA cases involving Xeljanz®, a medication for the treatment of rheumatoid arthritis. E.g., Pfizer Inc. et al. v. Prinston Pharmaceutical, Inc, 17-cv-123 (D. Del.)
- Pfizer, patent infringement ANDA cases involving Bosulif®, a medication for the treatment of leukemia. E.g., Wyeth LLC v. MSN Laboratories Private Ltd et al., 17-cv-233 (D. Del.)
- Acorda Therapeutics, trial counsel in patent infringement cases against ten generic drug manufacturers involving AMPYRA® (dalfampridine), an oral medication to improve walking in people with multiple sclerosis (MS). Acorda Therapeutics Inc. v. Actavis et al., 1:14-cv-00882-LPS (D. Del.).
- Cephalon, patent infringement case against ANDA-filer seeking FDA approval to market generic version of Cephalon's Treanda® injection product. Cephalon Inc. v. Fresenius Kabi USA, LLC, 1:15-cv-oo536-LPS (D. Del.)
- JD, Columbia Law School, 2014, Harlan Fiske Stone Scholar
- BA, New York University, 2011, magna cum laude, Phi Beta Kappa
- New York